Quick Answer
ADC Therapeutics SA reported Research And Development Expense of $104.01 million for the year ending 2025.
- ADC Therapeutics SA showed a decrease of -5.1% in Research And Development Expense from 2024 to 2025.
- This data is from ADC Therapeutics SA's annual report (Form 10-K), filed with the SEC on March 10, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $38.38 million | Q2 2023: $31.34 million | Q3 2023: $27.08 million | Q1 2024: $25.74 million | Q2 2024: $24.30 million | Q3 2024: $32.50 million | Q1 2025: $28.93 million | Q2 2025: $30.09 million | Q3 2025: $26.80 million.
- Over the full 8 years of available data (2018 to 2025), ADC Therapeutics SA's Research And Development Expense has declined by 12.1%.
- Historical annual values: Fiscal year 2025: $104.01 million | Fiscal year 2024: $109.63 million | Fiscal year 2023: $127.13 million | Fiscal year 2022: $186.46 million | Fiscal year 2021: $158.00 million | Fiscal year 2020: $142.03 million | Fiscal year 2019: $107.54 million | Fiscal year 2018: $118.31 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: